Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2017 (← Previous) (Next →)

Filing Date: Aug 2, 2017

Total Value: $127.1B (100.0% shares, 0.0% debt)

Holdings (8)

— Audentes Therapeutics, Inc. 27.2%

Value $34.58B Shares 1,806,832 Est. Cost $17810.00 Unrealized —

— Achaogen, Inc. 21.9%

Value $27.85B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— ImmuneDesign Corp. 16.8%

Value $21.31B Shares 2,208,210 Est. Cost $7580.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 16.2%

Value $20.54B Shares 2,215,384 Est. Cost $20.09 Unrealized -51.8%

— Clovis Oncology, Inc. 7.5%

Value $9.543B Shares 101,855 Est. Cost $56000.00 Unrealized —

— CymaBay Therapeutics, Inc. 4.8%

Value $6.04B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Second Sight Medical Products, Inc. 4.4%

Value $5.616B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— OpGen, Inc. 1.3%

Value $1.647B Shares 2,554,211 Est. Cost $1150.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Audentes Therapeutics, Inc.	1,806,832	$34.58B	27.2%	$17810.00	—	Common Stock	05070R104
—	Achaogen, Inc.	1,281,152	$27.85B	21.9%	$13050.00	—	Common Stock	004449104
—	ImmuneDesign Corp.	2,208,210	$21.31B	16.8%	$7580.00	—	Common Stock	45252L103
OCUL	Ocular Therapeutix, Inc.	2,215,384	$20.54B	16.2%	$20.09	-51.8%	Common Stock	67576A100
—	Clovis Oncology, Inc.	101,855	$9.543B	7.5%	$56000.00	—	Common Stock	189464100
—	CymaBay Therapeutics, Inc.	1,048,601	$6.04B	4.8%	$9830.00	—	Common Stock	23257D103
—	Second Sight Medical Products, Inc.	4,492,975	$5.616B	4.4%	$1210.00	—	Common Stock	81362J100
—	OpGen, Inc.	2,554,211	$1.647B	1.3%	$1150.00	—	Common Stock	68373L109